Charles A. Signorino, PhD
Charles A. Signorino, PhD is a Pharmtech editorial advisory board (EAB) member.
Charles A. Signorino, PhD
CEO
Emerson Resources, Inc.
Charles A. Signorino is the chief executive officer of Emerson Resources, Inc. He is an adjunct professor of pharmaceutics at the University of the Sciences in Philadelphia, and he has held positions at CS Associates Inc., Colorcon Inc., Eastern College, and Arco Chemical. His areas of expertise are aqueous enteric and film coating technology, FDA-approved colors and applications, pharmaceutical excipients, and rapid sugar coating.
Signorino is a member of the American Association of Pharmaceutical Scientists (AAPS), the American Chemical Society (ACS), and is also a member of the editorial advisory board for American Pharmaceutical Review. He has authored numerous technical publications, and he has given numerous seminars for various industry and academic events.
Signorino holds a BS from Pennsylvania State University, an MS and PhD from the University of Pennsylvania and an MAR from Westminster Theological Seminary.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
